tenofovir has been researched along with Bone Diseases, Metabolic in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (57.89) | 24.3611 |
| 2020's | 8 (42.11) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Meng, W; Song, Y; Xie, R; Zhang, F; Zhang, H | 1 |
| Blanco, JL; Callau, P; de la Mora, L; de Lazzari, E; Gonzalez-Cordón, A; Inciarte, A; Laguno, M; Mallolas, J; Martinez, E; Martinez-Rebollar, M; Rojas, J; Subirana, M; Torres, B | 1 |
| Guo, P; Qin, X; Yan, H; Yang, X; Zhang, X | 1 |
| Chang, J; Delgado, H; Do, D; Huynh, A; Kanimian, N | 1 |
| Li, L; Ma, W; Wei, D; Ye, P; Zeng, J | 1 |
| Bernasconi, E; Burkhalter, F; Calmy, A; Fellay, J; Günthard, HF; Hasse, B; Kahlert, CR; Kouyos, RD; Lamy, O; Ledergerber, B; Marzolini, C; Ryom, L; Schoepf, IC; Schwenke, JM; Tarr, PE; Thorball, CW; Wandeler, G | 1 |
| Alvarez-Barco, E; Mallon, PWG | 1 |
| Hadigan, CM; Hazra, R; Jones, SE; Kopp, JB; Mattingly, AS; Purdy, JB; Reynolds, JC; Unsal, AB | 1 |
| Brown, TT; Díez-Pérez, A; Fernandez Marron, A; García-Giralt, N; González-Mena, A; Guelar, A; Güerri-Fernández, R; Knobel, H; Lerma-Chippirraz, E; Soldado-Folgado, J; Trenchs-Rodríguez, M; Villar-García, J | 1 |
| Carr, A; Ebeling, PR; Hoy, JF; Kerr, SJ; Martinez, E; Pocock, N; Richardson, R; Rojas, J | 1 |
| Ahn, SH; Cho, YK; Choi, W; Han, KH; Hong, GY; Jang, JY; Jin, SY; Jung, YK; Kim, DJ; Kim, HS; Kim, JH; Kim, KH; Kim, MY; Kim, W; Kim, YJ; Kweon, YO; Lee, BS; Lee, JW; Lee, KS; Lee, WS; Lim, YS; Park, NH; Park, SJ; Sohn, JH; Um, SH; Yang, JM; Yim, HJ; Yoon, SK | 1 |
| Chang, MS; Cheung, R; Hsu, H; Le, AK; Nguyen, MH; Nguyen, P; Wei, MT; Wong, C; Zhang, JQ | 1 |
| Aldrovandi, G; Chan, C; Fischer, B; Goodenow, MM; Kim-Chang, JJ; Sleasman, JW; Venturi, G; Weber, TJ; Wilson, L | 1 |
| Cong, Z; Gu, R; Li, W; Liu, H; Wei, Q; Xue, J; Zhou, Y | 1 |
| Assoumou, L; Bentata, M; Costagliola, D; Katlama, C; Kolta, S; Roux, C; Rozenberg, S; Simon, A; Viard, JP | 1 |
| Becker, CB; Hamnvik, OP; Levy, BD; Loscalzo, J | 1 |
| Brooks, JT; Bush, T; Conley, L; Escota, GV; Hammer, J; Henry, K; Kojic, EM; Lichtenstein, KA; Mondy, K; Önen, N; Overton, ET; Patel, P; Wood, KC | 1 |
| Arribas, JR; Babiker, A; Bernardino, JI; Buño, A; Castagna, A; Chene, G; De Wit, S; Gerstoft, J; Girard, PM; Katlama, C; Mallon, PW; Mocroft, A; Raffi, F; Reiss, P; Richert, L; Russell, C; Wallet, C | 1 |
| Cotter, AG; Grant, PM | 1 |
4 review(s) available for tenofovir and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Comparison of renal safety and bone mineral density of tenofovir and entecavir in patients with chronic hepatitis B: a systematic review and meta-analysis.
Topics: Antiviral Agents; Bone Density; Bone Diseases, Metabolic; Hepatitis B, Chronic; Humans; Kidney; Osteoporosis; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Tenofovir-induced osteopenia and hyperparathyroidism: A case report and literature review.
Topics: Adenine; Bone Diseases, Metabolic; Calcium; Humans; Hyperparathyroidism, Primary; Hyperparathyroidism, Secondary; Osteoporosis; Tenofovir | 2022 |
What's new in bone disease and fractures in HIV?
Topics: Anti-HIV Agents; Bone Density; Bone Diseases, Metabolic; Fractures, Bone; HIV Infections; Humans; Tenofovir | 2021 |
Tenofovir and bone health.
Topics: Anti-HIV Agents; Bone Diseases, Metabolic; Fractures, Bone; HIV Infections; Humans; Tenofovir | 2016 |
3 trial(s) available for tenofovir and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV.
Topics: Absorptiometry, Photon; Adult; Aged; Anti-HIV Agents; Australia; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Drug Substitution; Female; Femur Neck; HIV Infections; Humans; Lumbar Vertebrae; Male; Middle Aged; Spain; Tenofovir; Treatment Outcome; Viral Load; Zoledronic Acid | 2018 |
Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection.
Topics: Absorptiometry, Photon; Adult; Alanine Transaminase; Antiviral Agents; Bone Density; Bone Diseases, Metabolic; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Female; Glomerular Filtration Rate; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Hip; Humans; Lumbar Vertebrae; Male; Maleates; Middle Aged; Organophosphonates; Osteoporosis; Renal Insufficiency; Sustained Virologic Response; Tenofovir; Treatment Outcome | 2019 |
Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Biomarkers; Bone Density; Bone Diseases, Metabolic; CD4 Lymphocyte Count; Comorbidity; Darunavir; Drug Therapy, Combination; Emtricitabine; Europe; Female; HIV Infections; Humans; Inflammation; Male; Middle Aged; Osteopetrosis; Raltegravir Potassium; Ritonavir; Tenofovir; Viral Load | 2015 |
12 other study(ies) available for tenofovir and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Prevalence and Risk Factors of Low Bone Mineral Density in HIV/AIDS Patients: A Chinese Cross-Sectional Study.
Topics: Absorptiometry, Photon; Acquired Immunodeficiency Syndrome; Bone Density; Bone Diseases, Metabolic; Cholesterol; Cross-Sectional Studies; HIV Infections; Humans; Lipoproteins, HDL; Middle Aged; Osteoporosis; Prevalence; Risk Factors; Tenofovir | 2022 |
Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Diseases, Metabolic; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Pilot Projects; Ritonavir; Tenofovir | 2022 |
A retrospective analysis of bone loss in tenofovir-emtricitabine therapy for HIV PrEP.
Topics: Anti-HIV Agents; Bone Diseases, Metabolic; Emtricitabine; HIV Infections; Humans; Osteoporosis; Retrospective Studies; Tenofovir | 2022 |
Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV: The Swiss HIV Cohort Study.
Topics: Bone Density; Bone Diseases, Metabolic; Cohort Studies; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Osteoporosis; Risk Factors; Switzerland; Tenofovir | 2023 |
Effect of Antiretroviral Therapy on Bone and Renal Health in Young Adults Infected With HIV in Early Life.
Topics: Absorptiometry, Photon; Acid-Base Equilibrium; Adult; Age of Onset; Albuminuria; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Case-Control Studies; Creatinine; Cross-Sectional Studies; Didanosine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Function Tests; Longitudinal Studies; Male; Osteocalcin; Prospective Studies; Proteinuria; Renal Insufficiency; Risk Factors; Stavudine; Tenofovir; Time Factors; Young Adult | 2017 |
Bone density, microarchitecture, and tissue quality after 1 year of treatment with tenofovir disoproxil fumarate.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Cancellous Bone; Female; Femur Neck; HIV Infections; Humans; Longitudinal Studies; Male; Severity of Illness Index; Spine; Tenofovir | 2018 |
Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Asian People; Bone Diseases, Metabolic; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Incidence; Male; Middle Aged; Osteoporosis; Proportional Hazards Models; Retrospective Studies; Tenofovir; Treatment Outcome; United States | 2019 |
Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy.
Topics: Adolescent; Alkaline Phosphatase; Anti-HIV Agents; Biomarkers; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Female; HIV Infections; Humans; Lymphocyte Activation; Macrophage Activation; Macrophages; Male; Osteopontin; Osteoprotegerin; Parathyroid Hormone; RANK Ligand; Tenofovir; Young Adult | 2019 |
Probiotics protect against tenofovir-induced mandibular bone loss in mice by rescuing mandible-derived mesenchymal stem cell proliferation and osteogenic differentiation.
Topics: Animals; Bone Diseases, Metabolic; Cell Proliferation; Humans; Male; Mandible; Mesenchymal Stem Cells; Mice; Osteogenesis; Probiotics; Tenofovir | 2020 |
Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Bone Density; Bone Diseases, Metabolic; Hip; HIV Infections; HIV-1; Humans; Lumbar Vertebrae; Male; Middle Aged; Organophosphonates; Risk Factors; Tenofovir | 2013 |
Clinical problem-solving. Wasting away.
Topics: Adenine; Adult; Bone Diseases, Metabolic; Cachexia; Diagnosis, Differential; Fanconi Syndrome; Female; Hepatitis B; Humans; Hypophosphatemia; Liver Function Tests; Organophosphonates; Pelvic Bones; Phosphates; Radiography; Reverse Transcriptase Inhibitors; Tenofovir | 2014 |
High Prevalence of Low Bone Mineral Density and Substantial Bone Loss over 4 Years Among HIV-Infected Persons in the Era of Modern Antiretroviral Therapy.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Apolipoproteins E; Bone Density; Bone Diseases, Metabolic; Case-Control Studies; CD4 Lymphocyte Count; Female; HIV; HIV Infections; Humans; Longitudinal Studies; Male; Middle Aged; Nutrition Surveys; Osteoporosis; Risk Factors; RNA, Viral; Tenofovir; United States | 2016 |